CELC
Celcuity Inc.
NASDAQ · USHealthcareBiotechnology
$87.99-0.44%
Price as of Jul 20, 2026
CELC growth
Celcuity Inc. growth
Reported trailing growth, forward expectations and three-year compound growth rates.
Trailing growth
Year over year
- Revenue
- —
- EBITDA
- -50.2%
- EBIT
- -47.0%
- EPS
- -28.4%
- Free cash flow
- -68.8%
- Operating cash flow
- -68.7%
Forward estimates
- Revenue
- —
- EBITDA
- —
- EPS
- +5.4%
Three-year CAGR
- Revenue
- —
- EBITDA
- -57.6%
- EBIT
- -52.0%
- Net income
- -58.4%
- EPS
- -33.6%
- Free cash flow
- -83.4%
Latest available reported and market-derived figures. A dash means the source dataset does not currently cover that metric; it does not imply a zero value.